SS
AVBP icon

SBI Securities’s ArriVent BioPharma AVBP Stock Holding History

SBI Securities’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$600 Sell
26
-20
-43% -$452 ﹤0.01% 2819
2025
Q4 		$926 Sell
46
-2
-4% -$42 ﹤0.01% 2672
2025
Q3 		$886 Buy
48
+23
+92% +$452 ﹤0.01% 2747
2025
Q2 		$544 Hold
25
– – ﹤0.01% 2934
2025
Q1 		$462 Hold
25
– – ﹤0.01% 2900
2024
Q4 		$666 Buy
+25
New +$718 ﹤0.01% 2787

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SBI Securities's AVBP Position: Q1 2026 in Review

SBI Securities reduced its ArriVent BioPharma (AVBP) stake by 43% in Q1 2026, selling an estimated $452 and leaving 26 shares worth $600. The position accounts for ﹤0.01% of the portfolio, ranked #2819.

SBI Securities first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $926 in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • SBI Securities held 26 shares of ArriVent BioPharma worth $600 as of Q1 2026.
  • SBI Securities sold 20 ArriVent BioPharma shares in Q1 2026, an estimated $452.
  • ArriVent BioPharma made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2819 holding.
  • SBI Securities first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's ArriVent BioPharma position peaked at $926 in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.